dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:20:55Z
dc.date.accessioned2022-10-05T17:50:36Z
dc.date.available2014-05-27T11:20:55Z
dc.date.available2022-10-05T17:50:36Z
dc.date.created2014-05-27T11:20:55Z
dc.date.issued2003-10-01
dc.identifierRevista Brasileira de Plantas Medicinais, v. 6, n. 1, p. 39-45, 2003.
dc.identifier1516-0572
dc.identifierhttp://hdl.handle.net/11449/67434
dc.identifier2-s2.0-0842328544
dc.identifier2-s2.0-0842328544.pdf
dc.identifier0679387622604743
dc.identifier6758680388835078
dc.identifier0000-0002-9227-832X
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3917080
dc.description.abstractThe pregnant women presenting Diabetes mellitus develop metabolic alterations, that may cause damage to the fetal well-being and provoke anomalies and/or malformations. The antioxidant treatment has improved the embryonic development from streptozotocin diabetic rats. Several studies have shown that a Gingko biloba extract presents antioxidant effects and, in the present study, one of the G. biloba extract formulations was used (EGb761) - Tebonin (200 mg/Kg/day), given to the diabetic pregnant female rats. The aim was to evaluate the effect of the EGb761 treatment on the of anomalies and/ or malformations incidence of the offspring. Diabetes was induced in female rats using streptozotocin in a dose of 40 mg/kg. The rats were mated, and the pregnant animals were divided in two groups: Control (water) and experimental (G. biloba). At day 21 of pregnancy, the rats were killed, and their fetuses were analyzed and processed for anomalies and/or malformations incidence. The results demonstrated that control and experimental groups presented no external anomalies and malformations; increased incidence of skeletal anomalies and of visceral malformations, and lower rate of visceral anomalies and skeletal malformations. These data confirm no statistical difference and, therefore, EGb761 treatment did not cause changes. Thus, a dose of 200 mg/Kg/day of a Gingko biloba extract given during the pregnancy rat was ineffective in the prevention of the anomalies and/or malformations related to the diabetes.
dc.languagepor
dc.relationRevista Brasileira de Plantas Medicinais
dc.relation0,199
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectDiabetes
dc.subjectGingko biloba
dc.subjectMalformations
dc.subjectPregnancy
dc.subjectRat
dc.subjectGinkgo biloba extract
dc.subjectplant extract
dc.subjectanimal model
dc.subjectantioxidant activity
dc.subjectbone malformation
dc.subjectcongenital malformation
dc.subjectcontrolled study
dc.subjectdiabetes mellitus
dc.subjectfetus malformation
dc.subjectGinkgo biloba
dc.subjectnonhuman
dc.subjectoxidative stress
dc.subjectpregnancy
dc.subjectrat
dc.subjectstreptozocin diabetes
dc.subjectAnimalia
dc.subjectGinkgo (genus)
dc.titleEstudo do extrato de Ginkgo biloba na prevenção de malformações em recémnascidos de ratas diabéticas
dc.typeArtigo


Este ítem pertenece a la siguiente institución